论文部分内容阅读
目的:对盐酸莫西沙星与头孢曲松钠联合阿奇霉素治疗中重度老年社区获得性肺炎进行疗效观察及成本-效果评价。方法:选取本院100例中重度老年社区获得性肺炎住院患者,随机分成盐酸莫西沙星组50例和头孢曲松钠联合阿奇霉素组50例,观察两组疗效并进行成本-效果分析。结果:盐酸莫西沙星组和头孢曲松钠联合阿奇霉素组总成本分别为2305.52元和2477.79元;总有效率分别为90.00%和84.00%(P>0.05);成本-效果比分别为25.62和29.50;药物不良反应发生率分别为8.00%和10.00%(P>0.05)。结论:盐酸莫西沙星的治疗方案为中重度老年社区获得性肺炎治疗的较好方案。
Objective: To observe the curative effect and cost-effectiveness of moxifloxacin hydrochloride combined with ceftriaxone sodium and azithromycin in the treatment of middle-aged and elderly patients with community-acquired pneumonia. Methods: A total of 100 elderly patients with community-acquired pneumonia admitted to our hospital were selected and randomly divided into 50 cases of moxifloxacin hydrochloride group and 50 cases of ceftriaxone sodium combined with azithromycin. The curative effect and cost-effectiveness of the two groups were observed. Results: The total costs of moxifloxacin hydrochloride group and ceftriaxone sodium combined with azithromycin group were 2305.52 yuan and 2477.79 yuan respectively. The total effective rates were 90.00% and 84.00%, respectively (P> 0.05). The cost-effectiveness ratios were 25.62 and 29.50 ; Adverse drug adverse reactions were 8.00% and 10.00% (P> 0.05). Conclusion: The treatment regimen of moxifloxacin hydrochloride is a good treatment for middle-aged and elderly patients with community-acquired pneumonia.